Not sure if you folks have seen this posting related to the Deeerfield investment:
“We are pleased to be able to support MannKind’s innovative efforts to advance the treatment of diabetes,” Deerfield General Partner James E. Flynn said in a statement. “Diabetes remains one of the most prevalent, fastest growing and most expensive diseases from a societal standpoint and efforts to fund more effective and more widely adopted therapies are essential.”
“We are encouraged by Deerfield’s confidence in the potential of Afrezza,” MannKind Chief Executive Alfred E. Mann said in a separate statement. “We worked with Deerfield to structure a facility that aligns with our near- and long-term strategy to achieve important development, commercial and strategic milestones while minimizing near term dilution.”
http://www.bizjournals.com/losangeles/news/2013/07/01/why-deerfield-is-investing-160m.html?ana=RSS&s=article_search&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+bizj_losangeles+%28Los+Angeles+Business+from+bizjournals%29
